ImmunityBio
Signal active
Organization
Contact Information
Overview
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks.
About
Industries
Health Care, Therapeutics, Health Diagnostics
Founded
2014
Employees
501-1000
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ImmunityBio headquartered in United States, North America, operates in the Health Care, Therapeutics, Health Diagnostics sector. The company focuses on Health Care and has secured $173.1B in funding across 156 round(s). With a team of 501-1000 employees, ImmunityBio is actively contributing to advancements in Health Care. Their latest funding round, Private Equity Round - ImmunityBio, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
13
Investors
1
Lead Investors
0
Total Funding Amount
$1109.7M
Details
3
ImmunityBio has raised a total of $1109.7M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Private Equity | 30.0M | ||
| 2016 | Private Equity | 57.0M | ||
| 2015 | Private Equity | 75.0M |
Investors
ImmunityBio is funded by 17 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| ImmunityBio | - | FUNDING ROUND - ImmunityBio | 10.0M |
| Oberland Capital | - | FUNDING ROUND - Oberland Capital | 10.0M |
| ImmunityBio | - | FUNDING ROUND - ImmunityBio | 75.0M |
| Patrick Soon-Shiong | - | FUNDING ROUND - Patrick Soon-Shiong | 75.0M |
Recent Activity
There is no recent news or activity for this profile.